We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Simply Wall St13:53 ET

Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder

MT NewswiresDec 3 10:59 ET

Express News | Intra-Cellular Therapies Submits Supplemental New Drug Application (Snda) to FDA for Caplyta® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

ReutersDec 3 07:30 ET

Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105

Moomoo NewsDec 2 08:32 ET · Ratings

Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100

Moomoo NewsNov 29 12:32 ET · Ratings

RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)

TipRanksNov 27 20:47 ET · Ratings